No Data
No Data
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare
Express News | HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target
Spero Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 316.67% HC Wainwright & Co. → $7 Reiterates Buy → Buy 04/04/2024 — Cantor Fitzgerald Reiterate
Buy Rating Affirmed for Spero Therapeutics Amidst Drug Pipeline Progress and Strategic Partnerships
Analysts Conflicted on These Healthcare Names: Spero Therapeutics (SPRO) and Coherus Biosciences (CHRS)
Spero Therapeutics Q1 2024 GAAP EPS $(0.24) Misses $(0.04) Estimate, Sales $9.267M Miss $21.533M Estimate
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.04) by 500 percent. This is a 4 percent increase over losses of $(0.2